Somewhat Positive Media Coverage Somewhat Unlikely to Affect Repros Therapeutics (RPRX) Share Price
Media coverage about Repros Therapeutics (NASDAQ:RPRX) has been trending somewhat positive this week, according to Accern Sentiment Analysis. The research group rates the sentiment of press coverage by reviewing more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Repros Therapeutics earned a news sentiment score of 0.21 on Accern’s scale. Accern also gave news headlines about the biotechnology company an impact score of 45.0743881619434 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.
Here are some of the headlines that may have impacted Accern’s rankings:
- Repros Therapeutics Inc (NASDAQ:RPRX) Gets Feedback Post An Oral Explanation With The EMA – USMarketsDaily (blog) (usmarketsdaily.com)
- Investors watching Analysts Rating of Repros Therapeutics Inc. (RPRX) – Wall Street Morning (wallstreetmorning.com)
- Repros Therapeutics Inc. (NASDAQ:RPRX) – Hair-Raising Facts to Know – Nasdaq Journal (press release) (nasdaqjournal.com)
- Conquer Concerns on Short-Term Commitments: Repros Therapeutics Inc. (NASDAQ:RPRX) – Stock News Stop (stockmarketstop.com)
- Evaluate Stock’s Volatility Before Making Any Investment Decision – Repros Therapeutics Inc., (NASDAQ: RPRX) – Stock Watch (stocksnewstimes.com)
Separately, S&P Equity Research cut their target price on shares of Repros Therapeutics from $0.49 to $0.39 in a research note on Monday, November 20th.
Repros Therapeutics (NASDAQ:RPRX) last announced its earnings results on Monday, November 13th. The biotechnology company reported ($0.04) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.28) by $0.24. Repros Therapeutics had a negative net margin of 4,242.73% and a negative return on equity of 894.22%. The company had revenue of $0.30 million for the quarter.
TRADEMARK VIOLATION NOTICE: This story was posted by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are accessing this story on another publication, it was copied illegally and republished in violation of U.S. & international trademark & copyright legislation. The legal version of this story can be accessed at https://theolympiareport.com/2017/12/21/somewhat-positive-media-coverage-somewhat-unlikely-to-affect-repros-therapeutics-rprx-share-price.html.
About Repros Therapeutics
Repros Therapeutics, Inc is a biopharmaceutical company focused on the development of new drugs to treat hormonal and reproductive system disorders. The Company’s product candidates include enclomiphene, which is a single isomer of clomiphene citrate, an orally active small molecule compound, and Proellex, which is an orally administered selective blocker of the progesterone receptor in women, for the treatment of uterine fibroids and endometriosis.
Receive News & Ratings for Repros Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repros Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.